Reimbursed Care Access in Haiti

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Haitian legislative texts and national lists explicitly identify "hallucinogenic mushrooms (psilocybin)" among narcotics subject to prohibition and criminal sanctions. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is not part of Haiti’s permitted medicinal formulary and is treated under the country’s narcotics control framework. #

Esketamine (Spravato) is not part of Haiti’s published national essential medicines list and there is no evidence of a national regulatory approval, implementation program, or public reimbursement pathway for esketamine-based psychiatric treatment in Haiti; therefore it is not an available reimbursed therapy within the Haitian health system. For context, esketamine is an approved, restricted, clinic-administered therapy in jurisdictions where it is registered (e.g., FDA approval in the United States). # #

Ketamine is included on Haiti’s national list of essential medicines and is used in clinical practice primarily as an anaesthetic agent, available in public and private health facilities for surgical and emergency indications. The Ministry of Public Health and Population (Ministère de la Santé Publique et de la Population, MSPP) national essential medicines list explicitly lists injectable ketamine preparations for use at multiple levels of care, indicating formal acceptance of ketamine for licensed medical indications (principally anaesthesia). Public reimbursement and coverage are limited by Haiti’s constrained health financing and supply-chain challenges; while ketamine is a listed essential medicine, availability and routine free-of-charge provision vary by facility and depend on stock and donor support rather than an established nationwide reimbursed psychiatric program. #

Off-label use of ketamine for psychiatric indications (e.g., treatment-resistant depression) is not an established, regulated, reimbursed pathway in Haiti. Where ketamine might be used off-label in low-resource or private settings, this would typically occur without formal national clinical guidance, standardized reimbursement, or widespread regulatory oversight; clinicians using ketamine for non-anaesthetic psychiatric purposes would be operating off-label and patients would generally bear treatment costs privately.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Haitian decrees and lists specifically name "Dimethyltryptamine (D.M.T.)" among hallucinogens prohibited except under formal exemptions for research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Although 5‑MeO‑DMT is not always enumerated separately in every national instrument, Haiti’s penal/decree framework criminalizes 'hallucinogenic' tryptamines and broadly covers natural and synthetic hallucinogens; therefore there is no authorised medical access or reimbursement. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no established regulatory pathway or reimbursed medical program for ibogaine in Haiti. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Haiti’s legal framework applies to DMT-containing preparations and broadly to natural or synthetic hallucinogens and their use, meaning there is no sanctioned medical or religious exemption that permits ayahuasca use as an authorised, reimbursed treatment. (Note: international conventions and many national laws do not separately regulate the plant brew when not explicitly listed; in Haiti, national texts expressly bring natural hallucinogenic substances within the scope of control.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Haitian drug control lists explicitly reference peyote/mescaline among hallucinogens under prohibition. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Haitian framework forbids new synthetic psychoactive substances and hallucinogens; specific 2C-series compounds are not therapeutically recognized or reimbursed in Haiti. #